Royalty Pharma plc
RPRXNASDAQHealthcare● Active
$54.86
$-1.01(-1.81%)
Market Cap$23.6B
P/E Ratio—
52W High$56.5
52W Low$33.4
Royalty Pharma plc (RPRX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RPRX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $1.32B | $1.33B | $1.70B | $0.23B | $1.24B |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.01B | $0.02B |
| Stock-Based Comp. | $0.29B | $0.00B | $0.00B | $0.00B | $0.00B |
| Change in Working Capital | ($0.02B) | $0.05B | $0.01B | $0.03B | ($0.02B) |
| Net Cash from Operations | $2.49B | $2.77B | $2.99B | $2.14B | $2.02B |
| Investing Activities | |||||
| Capital Expenditure | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Purchases of Investments | ($1.93B) | ($2.74B) | ($2.12B) | ($2.57B) | ($3.59B) |
| Sales of Investments | $0.57B | $0.12B | $0.03B | $1.55B | $1.78B |
| Net Cash from Investing | ($1.61B) | ($2.68B) | ($2.07B) | ($1.03B) | ($1.87B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($1.23B) | ($0.23B) | ($0.30B) | $0.00B | $0.00B |
| Dividends Paid | ($0.38B) | ($0.38B) | ($0.36B) | ($0.33B) | ($0.29B) |
| Debt Issued / Repaid | $0.95B | $1.47B | ($1.00B) | $0.00B | $1.27B |
| Net Cash from Financing | ($1.19B) | $0.36B | ($2.15B) | ($0.94B) | $0.39B |
| Free Cash Flow | |||||
| Free Cash Flow | $2.49B | $2.77B | $2.99B | $2.14B | $2.02B |
| FCF Margin %(computed) | 104.69% | 122.33% | 126.89% | 95.83% | 88.12% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Royalty Pharma plc data
About Royalty Pharma plc (RPRX) Cash Flow Statement
Royalty Pharma plc generated operating cash flow of $2.49B and free cash flow of $2.49B for 2025 — a FCF margin of 104.69%. Capital expenditure was $0.00B.
Frequently asked questions
RPRX · 4 questionsRoyalty Pharma plc generated free cash flow of $2.49B for 2025, down 10.1% year-over-year.
RPRX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10